We rank companies based on fund manager, research analyst and news sentiment
GCTK stock icon



About: GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.

Employees: 6

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

7.95% less ownership

Funds ownership: 10.84% [Q3] → 2.89% (-7.95%) [Q4]

22% less funds holding

Funds holding: 9 [Q3] → 7 (-2) [Q4]

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

73% less capital invested

Capital invested by funds: $594K [Q3] → $158K (-$436K) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Research analyst outlook

We haven’t received any recent analyst ratings for GCTK.

Financial journalist opinion